EyeBio
FranceWho owns EyeBio?
EyeBio is a French Biotech company, now owned by Merck, which acquired it in 2024 from SV Health Managers and Jeito Capital.
Hand-verified · updated 2026-09-30
Open JSON · CC-BY
- ·Fully exited in 2024 to Merck (MSD).
- ·Average hold across 2 realized cycles: 3 years.
Ownership history
2 ownership periods · co-invest detected
SV Health Managers sold EyeBio to Merck in 2024 after 3 years.
Jeito Capital sold EyeBio to Merck in 2024 after 2 years.
More from Jeito I
Other portfolio companies in the same fund.
Switzerland
Spain
Germany
DenmarkMore PE-backed in Biotech
Comparable biotech deals from other GPs.
USQuestions
Who owns EyeBio?
EyeBio is now owned by Merck, which acquired it in 2024 from SV Health Managers and Jeito Capital.
When did Merck acquire EyeBio?
Merck acquired EyeBio in 2024, buying from SV Health Managers and Jeito Capital.
Who did EyeBio sell to?
SV Health Managers and Jeito Capital sold EyeBio to Merck in 2024 (Trade Sale).
Who has owned EyeBio over time?
EyeBio has been through 2 private-equity ownership periods: SV Health Managers · via SV7 Impact Medicine Fund · 2021–2024 · sold to Merck · (Trade Sale); Jeito Capital · via Jeito I · 2022–2024 · sold to Merck · (Trade Sale).